Our animal experiments revealed that talazoparib induced FGFR3 phosphorylation, and that PD173074 dose-dependently inhibited talazoparib-induced FGFR phosphorylation in tumor tissues harvested 3 days after treatment (Supplemental Figure 9A). The gene discussed is FGFR3; the disease is neoplasm.